Tirol Kliniken GmbH
- Address
- Anichstrasse 35, 6020 Innsbruck, Austria
Tirol Kliniken GmbH - Comprehensive Hematology-Oncology and Cardiovascular Research Center
Tirol Kliniken GmbH is a leading academic medical center with demonstrated excellence in hematologic malignancies and cardiovascular disease research. The center's research portfolio reflects a strong commitment to advancing treatment paradigms through participation in pivotal Phase III trials, with particular emphasis on acute myeloid leukemia (AML) and other complex blood disorders, as well as high-risk cardiovascular conditions.
- Acute Myeloid Leukemia (AML) - Multiple Phase III trials investigating novel therapeutic combinations including venetoclax and CPX-351 in newly diagnosed patients with various genetic risk profiles
- Pediatric Hematology-Oncology - International collaborative research in Langerhans Cell Histiocytosis (LCH) focusing on treatment optimization and reduction of late sequelae in children and adolescents
- Lymphoma Research - Advanced immunotherapy trials combining novel bispecific antibodies with chemotherapy for follicular lymphoma
- Cardiovascular Risk Management - Biomarker-driven approaches to preventing recurrent cardiovascular events in post-myocardial infarction patients
The center's research infrastructure supports complex randomized controlled trials across multiple therapeutic areas, with expertise in both intensive chemotherapy regimens and targeted molecular therapies. Their participation in international collaborative protocols demonstrates a commitment to advancing precision medicine approaches and improving outcomes for patients with high-risk hematologic malignancies and cardiovascular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Universitaetsklinikum Ulm AöR1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Universitaetsklinikum Ulm AöR2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tirol Kliniken GmbH
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2) | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 3 | Unknown | 2019-08-28 | 2024-10-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.